'Tis the season of clichés

Google informs me that the advice to "sell in May, and go away" comes from the tradition of British merchant bankers—I presume in the 19th century—to leave London for the country side in May and come back on St Leger's Day in September. I am partial to a good anecdote, but does it work? In order to check, I ran a little study using the S&P 500 going back to 1991. The first chart below shows the returns you would have foregone by selling in May and waiting 35 weeks and 17 weeks, respectively, before buying back. I have included both mean and median returns, because the outliers can skew the former when your sample size is not large. The second chart shows the results of a strategy which shorts the S&P 500 in May, buys the first week of October, and holds until year end.

Read More
The AS guide to company analysis

Another weekend another unpredictable political bingo, this time in France. I have a lot to say about this, but little of it has any value because like most of you, I have no particular insight into what the final outcome will be. My suggestion, buy some good French cheese and a nice bottle of Vacqueyras, sit back and just let it happen.

It would be pointless for me to go through my views on the market in this context. Instead, I thought that I would do a bit of legwork on company analysis. I don't often present this part of my work here, but I thought that I would make an exception. Think of it as an alternative way to look at the headline fundamentals, compared to what you see by the sell side. Picking the companies to analyse is an art in itself—in the sense that you can't look at everything—so I thought that I would run the charts and analysis for Johnson & Johnson, a stalwart U.S. blue chip value and dividend aristocrat. It's a good benchmark for this type of analysis, because it has a long and well-updated history of data, and because it will be easy for you to judge the analysis given the tons of information already available on this firm.

Read More
claus vistesen
Let's stick to what we know

Investors have found it difficult to resist the temptation to become armchair generals in response to the recent flurry of geopolitical volatility. I have some sympathy for that. Political experts told us that Mr. Trump would mark the beginning of a new U.S. isolationism, and even speculated about the emergence of a new Monroe doctrine. The president's "America First" discourse, the statement that NATO is obsolete, and the rapprochement to Russia were all pivots watched ominously by other world leaders, especially in continental Europe.

This story, however, increasingly feels like ancient history.

Read More
Good News and Bad News

The bad news is that investors once again has to play armchair generals in the next few sessions as they try to gauge the importance of the Mr. Trump's sudden decision to put his foot down in Syria. There are no easy way to break this to investors. There is a lot stuff going on and even more well-minded "experts" who are ready to tell you what to do about it. The good news is that I am going to spare you my hot takes on this occasion, because I am going on holiday. My destination is Madrid, so please do look me up if you want a cerveza. I can most likely be found in one of El Prado's majestic halls. Assuming you lot haven't started a nuclear war and blown me to smithereens, I hope to be back next weekend with some more market-related meat and potatoes.

Read More